Filtered By:
Specialty: Research
Nutrition: Vitamins

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 47 results found since Jan 2013.

Impact of the COVID-19 pandemic on England's national prescriptions of oral vitamin K antagonist (VKA) and direct-acting oral anticoagulants (DOACs): An interrupted time series analysis (January 2019 - February 2021)
Conclusion: The overall oral anticoagulants use in this period was lower than expected, indicating a medical needs gap, possibly due to adherence issues. The potential clinical and logistical consequences warrant further study to identify contributing factors and mitigate avoidable risks.PMID:35582854 | DOI:10.1080/03007995.2022.2078100
Source: Current Medical Research and Opinion - May 18, 2022 Category: Research Authors: Sajidah Alkhameys Ravina Barrett Source Type: research

Medium to long-term persistence with non-vitamin K oral anticoagulants in patients with atrial fibrillation: Australian experience.
CONCLUSIONS: Long-term persistence with anticoagulation in patients with AF remains a concern, even with NOACs. Patients initiated to apixaban appear to experience better medium-term persistence compared with rivaroxaban or dabigatran. PMID: 28425296 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - April 22, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research

Vitamin D, Cardiovascular Disease and Risk Factors.
Authors: Skaaby T, Thuesen BH, Linneberg A Abstract Observational studies have suggested a possible protective role of vitamin D on the cardiovascular system. The available evidence does not support either cardiovascular benefits or harms of vitamin D supplementation. This chapter provides an overview and discussion of the current knowledge of vitamin D effects from a cardiovascular health perspective. It focuses on vitamin D in relation to cardiovascular disease, i.e. ischemic heart disease, and stroke; the traditional cardiovascular risk factors hypertension, abnormal blood lipids, obesity; and the emerging risk ...
Source: Advances in Experimental Medicine and Biology - November 12, 2017 Category: Research Tags: Adv Exp Med Biol Source Type: research

Influence of age on the pharmacokinetics, pharmacodynamics, efficacy, and safety of rivaroxaban.
CONCLUSION: A favorable clinical profile with rivaroxaban was observed across age subgroups, supporting the premise that dosing in older adults does not necessitate adjustment. However, it is prudent that a cautious and individualized approach is taken for treatment with any anticoagulant in older adults. PMID: 29932775 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - June 28, 2018 Category: Research Tags: Curr Med Res Opin Source Type: research

A rapid evidence assessment of bleed-related healthcare resource utilization in publications reporting the use of direct oral anticoagulants for non-valvular atrial fibrillation.
CONCLUSIONS: The limited available evidence for HRU burden among patients receiving oral anticoagulation for NVAF suggests that DOACs (particularly apixaban and dabigatran) offer some degree of benefit in terms of HRU outcomes, compared with warfarin. Further work is required to understand HRU outcomes in patients receiving DOACs. PMID: 30380959 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - November 2, 2018 Category: Research Tags: Curr Med Res Opin Source Type: research

A descriptive pilot study of mitochondrial mutations & clinical phenotype in fibromyalgia syndrome.
A descriptive pilot study of mitochondrial mutations & clinical phenotype in fibromyalgia syndrome. Indian J Med Res. 2019 Jan;149(1):47-50 Authors: Danda S, Thomas BM, Paramasivam G, Thomas R, Mathew J, Danda D Abstract Background & objectives: : Fibromyalgia syndrome (FMS) is one of the most common chronic pain conditions of unknown aetiology. Mitochondrial dysfunction has been reported in FMS with some studies reporting the presence of mitochondrial mutation namely A3243G, which also causes mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes. This pilot study was condu...
Source: Indian J Med Res - December 31, 2018 Category: Research Authors: Danda S, Thomas BM, Paramasivam G, Thomas R, Mathew J, Danda D Tags: Indian J Med Res Source Type: research

Impact of methodological choices on a meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation.
Conclusions Sensitivity analyses showed the impact of similar assumptions was different depending on the outcome, and the drug considered. The development of recommendations and guidelines for the inclusion of RWE in meta-analyses could prove useful in evaluating the effectiveness of health care interventions. PMID: 31328580 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - July 24, 2019 Category: Research Tags: Curr Med Res Opin Source Type: research

Minor bleeding in patients with atrial fibrillation using a non-vitamin K antagonist oral anticoagulant.
Conclusion: Our data showed that minor bleeds are common in novel NOAC users, especially when using apixaban and rivaroxaban. In the latter two NOACs, hematoma (bruises) and nose bleeds were more frequently observed and accounted for the difference with dabigatran. Besides type of NOAC, a higher HAS-BLED score and novel anticoagulant drug use were associated with an increased risk of minor bleeding. PMID: 32573287 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - June 24, 2020 Category: Research Tags: Curr Med Res Opin Source Type: research

Therapeutic effect of antithrombotic drug combinations in patients with atrial fibrillation undergoing percutaneous coronary intervention for coronary heart disease: a meta-analysis
CONCLUSIONS: DAT with NOACs has a higher safety profile against bleeding in patients with atrial fibrillation after PCI. DAT with VKAs was similar to TAT in terms of antithrombotic effect and incidence of bleeding.PMID:36628223 | PMC:PMC9827321
Source: American Journal of Translational Research - January 11, 2023 Category: Research Authors: Huabin He Xifeng Xiao Xiangyang Yuan Jianhai Chen Source Type: research